growth | pharmaphorum

Skip to main content

Friday 20 March 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

growth

Sales & Marketing

Paul Shawah and Mike Josey interview

Sponsored

Vault CRM Campaign Manager: Supporting high growth by synchr...

Veeva's Paul Shawah and Essential Pharma's Mike Josey discuss Vault CRM Campaign Manager in this video feature.

Sales & Marketing

demerging puzzle pieces

Unlocking impact and growth at times of demerger

Pharma and medtech companies have undergone unprecedented growth through aggressive M&A over the

Market Access

private equity

Growing healthcare businesses with private equity

Healthcare companies perform a critical role in society globally.

R&D

Ireland coast line

Why Ireland has emerged as Europe’s biopharma hotspot

Ireland is attracting major investment from the largest pharma companies in the world.

Sales & Marketing

medical writing

Global upswing in medical writing, with a bout of M&A

Swift pharma R&D growth has accelerated growth of associated industries, like medical writing.

Market Access

population of the world

Why we need to support healthcare’s vital acceleration

What do I mean by vital acceleration?

Editor's Picks

NVIDIA sinks $2bn into AI cloud provider Nebius

Incyte breaks new ground in anal cancer with EU approval

Novo rapped by FDA for not reporting drug adverse effects

Iran hackers claim cyberattack at US medtech firm

Veeva buys brand engagement firm Ostro for $100m

News

Kidney biotech R1's $78m debut, and other biofinancings

Kidney biotech R1's $78m debut, and other biofinancings

Biofinancing values have tailed off a bit after a strong start to 2026, but March has seen $50m+ rounds for R1, Crossbow, Excalipoint, and Prolium.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights further

Sponsored

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company